826 abstracts found.



Results filter

A CRUK phase I trial of adoptive transfer of autologous tumour antigen-specific T cells with pre-conditioning chemotherapy and intravenous IL2 in patients with advanced CEA positive tumours

Year:

Session type:

Fiona Thistlethwaite (1), Ryan Guest (2), Dominic Rothwell (2), Andrea Byatte (1), Eyad Elkord (2), Natalia Kirillova (2), Nigel Westwood (3), Eric Austin (4), David Gilham (2), Robert Hawkins (2)
The Christie NHS Foundation Trust, Manchester, United Kingdom (1), The University of Manchester, Manchester, United Kingdom (2), Cancer Research UK, London, United Kingdom (3), NHSBT, Manchester, United Kingdom (4)

Translational studies of the TeloVac trial: Characterisation of the immune response to GV1001

Year:

Session type:

Victoria Shaw (1), Dean Naisbitt (2), Eithne Costello (1), John Farrell (2), Kevin Park (2), John Neoptolemos (1), Gary Middleton (3)
Liverpool CR-UK Centre, University of Liverpool, Liverpool, United Kingdom (1), MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, United Kingdom (2), St Lukes Cancer Centre, Royal Surrey County Hospital NHS Trust, Guildford, United Kingdom (3)

An advanced computerised decision support technology to support breast multidisciplinary meetings

Year:

Session type:

Vivek Patkar (1), Dionisio Acosta (1), Alison Jones (2), John Fox (3), Mo Keshtgar (2)
University College London, London, United Kingdom (1), Royal Free Hospital, London, United Kingdom (2), Oxford university, Oxford, United Kingdom (3)

The link between insulin resistance and obesity and prostate tumor markers development in adult men

Year:

Session type:

MAJED ALOKAIL (1), NASER AL-DAGHRI (1), OMAR AL-ATTAS (1), AXEL ULLRICH (2)
KING SAUD UNIVERSITY, RIYADH, Saudi Arabia (1), Max Planck Institute of Biochemistry, Martinsried,, Germany (2)

Effects of nanosecond pulsed electric field (nsPEF) on human liver cancer cells in vitro

Year:

Session type:

Cheng Jie (1), Tang Liling (1)
College of Bioengineering,Chongqing University, Chongqing, China (1)

AZ6522 is a potent inhibitor of polo-like kinases with pharmacodynamic and anti-tumour activity in xenograft models

Year:

Session type:

Barry Davies (1), Gareth Hughes (1), Elaine Brown (1), David Rudge (1), Madeleine Brady (1), Joanne Wilson (1), Stephen Green (1)
AstraZeneca, Macclesfield, United Kingdom (1)

Functional impairment of the p53 pathway detected by flow cytometry is an independent predictor of early progression and short survival in chronic lymphocytic leukaemia (CLL)

Year:

Session type:

Ke Lin (1), Anthony Carter (1), Nichola Rockliffe (1), Gillian Johnson (1), Melanie Oates (1), Thorsten Zenz (2), Stephan Stilgenbauer (2), Mark Atherton (3), Angela Douglas (3), Andrew Pettitt (1)
Liverpool Cancer Research UK Centre, School of Cancer Studies, University of Liverpool, Liverpool, United Kingdom (1), Department of Internal Medicine III, University of Ulm, Ulm, Germany (2), Cheshire and Merseyside Genetics Laboratories, Liverpool Women's Hospital, Liverpool, United Kingdom (3)

Tie2-expressing macrophages drive recovery of murine mammary tumours after treatment with the vascular-damaging agent, combretastatin A-4-phosphate.

Year:

Session type:

A F Welford (1), S B Coffelt (2), M A Venneri (3), D Biziato (3), M Fisher (1), M De Palma (3), G M Tozer (1), C E Lewis (2)
Tumour Microcirculation group, University of Sheffield, Sheffield, United Kingdom (1), Tumour Targeting Group, Sheffield, United Kingdom (2), Angiogenesis and Tumour Targeting Research Unit, San Raffaele Institute, Milan, Italy (3)

SCALOP: A CRUK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer.

Year:

Session type:

Somnath Mukherjee (1), Chris Hurt (2), Gareth Griffiths (2), Tom Crosby (3), John Staffurth (3), Sarah Bridges (2), John Bridgewater (4), Alec McDonald (5), Stephen Falk (6), Ross Abrams (7), Timothy Maughan (3), George Joseph (3), Bethan Tranter (3), Wendy Wade (3), Paul Morris (8)
Northampton General Hospital, Northampton, United Kingdom (1), Wales Cancer Trials Unit, Cardiff, United Kingdom (2), Velindre Cancer Centre, Cardiff, United Kingdom (3), Royal Free&University College Medical School, London, United Kingdom (4), Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom (5), Bristol Haematology and Oncology Centre, Bristol, United Kingdom (6), Rush University Medical Centre, Chicago, United States (7), Patient representative, Cardiff, United Kingdom (8)

Functional characterization of SET8 in prostate cancer cell lines

Year:

Session type:

Dhuha Alkharaif (1), Kelly Armstrong (1), Craig Robson (1)
Newcastle University, Newcastle Upon Tyne, United Kingdom (1)

Page 25 of 83« First...25...50...Last »